Precision Targeting for Liver Cancer Therapeutics
Leveraging clinically validated hepatotropic mechanisms
to enable tumor-selective delivery of therapeutic payloads.
“¢ Clinically validated liver-targeting approach
“¢ Dual imaging and therapeutic platform
“¢ Designed for tumor retention
Our Approach
We are developing a radiotheranostic platform that uses clinically validated liver-targeting biology to deliver radioactive payloads to tumors.
By leveraging endogenous hepatic transport mechanisms, our approach is designed to enable tumor targeting while supporting clearance from normal tissue.
Pipeline
Lead Program – Radiotherapeutic platform – Preclinical
Imaging Agent – Diagnostic platform – Preclinical
Our platform is designed to enable expansion into additional malignancies.
Team
Khashayar Vakili, M.D.
Founder, Chief Executive Officer & Chief Scientific Officer
Hepatobiliary and liver transplant surgeon with over 15 years of experience in liver cancer biology and translational research, with a focus on developing novel therapeutic approaches for liver malignancies.
Scientific Advisors
Alan Packard, Ph.D. – Boston Children’s Hospital & Harvard Medical School
Anthony Belanger, Ph.D. – Dana Farber Cancer Institute & Harvard Medical School
Caroline Benn, Ph.D. – LoQus23 Therapeutics
Momentum
Building toward clinical translation
Selected for MassChallenge Healthcare Traction Program 2026
Supported by National Cancer Institute / NIH funding
Partner with us
We are seeking strategic partners and investors to advance our platform toward clinical development.
contact@zeest.bio